Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings

For the quarter ended March 2025, Alkermes (ALKS) reported revenue of $306.51 million, down 12.5% over the same period last year. EPS came in at $0.13, compared to $0.44 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $316.7 million, representing a surprise of -3.22%. The company delivered an EPS surprise of -53.57%, with the consensus EPS estimate being $0.28.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Alkermes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Manufacturing and Royalty revenues: $62.02 million versus the five-analyst average estimate of $65.33 million. The reported number represents a year-over-year change of -46.9%.
• Revenues- Product sales, net: $244.49 million versus $254.16 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.7% change.
• Revenues- Proprietary Sales- VIVITROL: $101 million versus the four-analyst average estimate of $98.71 million. The reported number represents a year-over-year change of +3.4%.
• Revenues- Proprietary Sales- ARISTADA: $73.50 million versus $78.52 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -6.8% change.
• Revenues- Proprietary Sales- LYBALVI: $70 million versus $70.91 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +22.8% change.
• Revenues- Key Commercial Product Revenues- VUMERITY: $27.80 million versus the three-analyst average estimate of $27.81 million. The reported number represents a year-over-year change of -11.1%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research